Infliximab (Remicade®) is a chimeric human/mouse monoclonal antibody that targets tumor necrosis factor alpha (TNFα).

Excess amounts of TNFα are associated with the development of immune diseases. Infliximab neutralizes the biological activity of TNF-α by inhibiting effective binding of TNF-α with its receptors.

Extracellular, transmembrane, and receptor-bound forms of TNF-α are all neutralized by infliximab. Neutralizing TNF-α activity results in dampening of the immune response. Treatment with infliximab has been described to decrease signs and symptoms of various auto-immune disease. 

Clinical use

In Europe, infliximab is indicated for the treatment of:

  • rheumatoid arthritis (in combination with methotrexate) 
  • psoriatic arthritis
  • rheumatoid colitis
  • ulcerative Crohn disease
  • psoriasis
  • ankylosing spondylitis.

What can Sanquin do for you?

  • Measure levels of free drug in the serum; levels of therapeutic antibodies are assessed using validated ELISAs.
  • Measure the immunogenicity of adalimumab; human anti-human antibodies are quantified using validated antigen-binding tests (radioimmunoassay or RIA).

Send in samples

 To use our drug level and ADA testing services, fill out this form and send it to us along with 1 mL frozen serum sample per patient.